ABSTRACT

Factor IX and factor X have sialic acid in O-linked and N-linked oligosaccharides on their activation peptides, and a terminal sialic acid is found on a recently described O-linked tetrasaccharide at Ser-61 in the light chain of human factor IXa. In studies presented here, the potential role of sialic acid residues in mediating activity of human coagulation factors IX and X was tested after enzymatic removal of sialic acid residues. In contrast to previous reports, treatment of factor IX or factor IXa with recombinant sialidase did not decrease the rate of factor IX activation or proteolytic properties of human factor IXa. The activation rates of factor IX and desialated factor IX were indistinguishable when treated with factor XIa, with factor VIIa/tissue factor complex, and with the factor X activating enzyme from Russell's viper venom. Desialated human factor IXa showed full activity in the non-activated partial thromboplastin time assay and retained full ``tenase'' activity in a coupled amidolytic assay. Similar experiments with human factor X showed no detectable loss of clotting activity in the prothrombin time assay after desialation. Additionally, desialated human factor X was cleaved by the factor X activating enzyme from Russell's viper venom and intrinsic tenase at the same rate as untreated factor X when analyzed by SDS-polyacrylamide gel electrophoresis. These studies have shown that factor IX and factor X clotting activity are not dependent on sialic acid content. Further studies are needed to determine whether desialated factor IX binds to endothelial cells, and whether factors IX and X are more rapidly cleared from circulation or have altered susceptibility to proteolysis after enzymatic removal of sialic acid.

FOOTNOTES

*

This investigation was supported by grants from Blood Systems Foundation, Scottsdale, AZ (to K. J. S. and W. K.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§

To whom correspondence should be addressed.

()

The abbreviations used are: EGF, epidermal growth factor; AT-III, antithrombin III; NAPTT, non-activated partial thromboplastin time; PAGE, polyacrylamide gel electrophoresis; PTT, partial thromboplastin time; RVV-X, factor X activating emzyme from Russell's viper venom; TBS, Tris-buffered saline; t-PA, tissue plasminogen activator.

ACKNOWLEDGEMENTS

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				G.-C. Gil, W. H Velander, and K. E Van Cott Analysis of the N-glycans of recombinant human Factor IX purified from transgenic pig milk Glycobiology, July 1, 2008; 18(7): 526 - 539. [Abstract] [Full Text] [PDF]

				V. B. Louvain-Quintard, E. P. Bianchini, C. Calmel-Tareau, M. Tagzirt, and B. F. Le Bonniec Thrombin-activable Factor X Re-establishes an Intrinsic Amplification in Tenase-deficient Plasmas J. Biol. Chem., December 16, 2005; 280(50): 41352 - 41359. [Abstract] [Full Text] [PDF]

				J. A. Fernandez, T. M. Hackeng, K. Kojima, and J. H. Griffin The Carbohydrate Moiety of Factor V Modulates Inactivation by Activated Protein C Blood, June 15, 1997; 89(12): 4348 - 4354. [Abstract] [Full Text] [PDF]

				S. R. Pirie-Shepherd, R. D. Stevens, N. L. Andon, J. J. Enghild, and S. V. Pizzo Evidence for a Novel O-Linked Sialylated Trisaccharide on Ser-248 of Human Plasminogen 2 J. Biol. Chem., March 14, 1997; 272(11): 7408 - 7411. [Abstract] [Full Text] [PDF]

				R. J. Baugh and S. Krishnaswamy Role of the Activation Peptide Domain in Human Factor X Activation by the Extrinsic Xase Complex J. Biol. Chem., July 5, 1996; 271(27): 16126 - 16134. [Abstract] [Full Text] [PDF]